title: Randomised double-blind study comparing tropisetron alone and in combination with dexamethasone in the prevention of acute and delayed cisplatin-induced emesis.
abstract: In a randomised, double-blind and parallel-design multicentre study, 282 chemotherapy-naive cancer patients received tropisetron 5 mg intravenously (i.v.) before high-dose cisplatin on day 1, and oral tropisetron 5 mg daily on days 2-6, in combination with either placebo (n = 143) or dexamethasone (n = 135), given i.v. on day 1 and orally on days 2-6. Complete protection from acute vomiting/nausea was achieved in 76.3%/79.3% of patients receiving the combination and in 55.2%/61.5% of those receiving tropisetron alone. Complete protection on days 2-6 from delayed vomiting/nausea was obtained in 60%/60% and 39.2%/40.6%, respectively. Tropisetron in combination with dexamethasone is safe and more effective than tropisetron alone in the prevention of both acute and delayed cisplatin-induced emesis.
authors.affiliation: Institut Català d'Oncologia, Hospital Duran i Reynals, Dept. of Medical Oncology, Barcelona, Spain.
authors.forename: X
authors.initials: X
authors.lastname: Garcia-del-Muro
authors.forename: C
authors.initials: C
authors.lastname: Vadell
authors.forename: G
authors.initials: G
authors.lastname: Pérez Manga
authors.forename: I
authors.initials: I
authors.lastname: Bover
authors.forename: J
authors.initials: J
authors.lastname: Rifá
authors.forename: M
authors.initials: M
authors.lastname: Beltrán
authors.forename: M M
authors.initials: MM
authors.lastname: Barros
authors.forename: J R
authors.initials: JR
authors.lastname: Germá
authors.forename: X
authors.initials: X
authors.lastname: Fabregat
authors.forename: V
authors.initials: V
authors.lastname: Moreno
authors.forename: A
authors.initials: A
authors.lastname: Salvador
authors.forename: P
authors.initials: P
authors.lastname: Viladiu
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000932:Antiemetics / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002945:Cisplatin / Q000009:adverse effects*; D003907:Dexamethasone / Q000008:administration & dosage*; D004311:Double-Blind Method; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007211:Indoles / Q000008:administration & dosage*; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced / Q000517:prevention & control*; D016896:Treatment Outcome; D000077526:Tropisetron; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control*
chemical_list: D000932:Antiemetics; D000970:Antineoplastic Agents; D004338:Drug Combinations; D007211:Indoles; D000077526:Tropisetron; D003907:Dexamethasone; D002945:Cisplatin